Combination therapies to improve the long-term outcome in hairy cell leukemia
Combination therapies to improve the long-term outcome in hairy cell leukemia
Since its first description in 1958, hairy cell leukemia (HCL) had a long period of different unsatisfactory treatments till the early 1980s, when interferon-alfa and subsequently purine analogs (PAs) pentostatin or cladribine, or pentostatin were described to determine durable responses. However, second lines of treatments are very often needed in the life span of patients with HCL and a small minority of patients are refractory and with poor prognosis. These disadvantages have led to test the efficacy of additional compounds, mainly monoclonal antibodies, combined with PAs. The objective of this presentation is to review the current knowledge of combination treatments in HCL. Combination treatments have been used or proposed for different purposes in HCL: to reduce acute toxicity, to improve complete remission (CR) rate, to overcome resistance/refractoriness, to prolong disease-free survival, or to prolong overall survival. The type of patients to be selected for the combinations and the perspectives of combinations of PAs with monoclonal antibodies will also be discussed.
hairy cell leukemia, purine analogs, rituximab, combination therapy, outcome
18-22
Lauria, Francesco
f01f163b-abcb-4aad-b952-f4356692f519
Forconi, Francesco
ce9ed873-58cf-4876-bf3a-9ba1d163edc8
October 2009
Lauria, Francesco
f01f163b-abcb-4aad-b952-f4356692f519
Forconi, Francesco
ce9ed873-58cf-4876-bf3a-9ba1d163edc8
Lauria, Francesco and Forconi, Francesco
(2009)
Combination therapies to improve the long-term outcome in hairy cell leukemia.
Leukemia and Lymphoma, 50, supplement 1, .
(doi:10.3109/10428190903142273).
(PMID:19814693)
Abstract
Since its first description in 1958, hairy cell leukemia (HCL) had a long period of different unsatisfactory treatments till the early 1980s, when interferon-alfa and subsequently purine analogs (PAs) pentostatin or cladribine, or pentostatin were described to determine durable responses. However, second lines of treatments are very often needed in the life span of patients with HCL and a small minority of patients are refractory and with poor prognosis. These disadvantages have led to test the efficacy of additional compounds, mainly monoclonal antibodies, combined with PAs. The objective of this presentation is to review the current knowledge of combination treatments in HCL. Combination treatments have been used or proposed for different purposes in HCL: to reduce acute toxicity, to improve complete remission (CR) rate, to overcome resistance/refractoriness, to prolong disease-free survival, or to prolong overall survival. The type of patients to be selected for the combinations and the perspectives of combinations of PAs with monoclonal antibodies will also be discussed.
This record has no associated files available for download.
More information
Published date: October 2009
Keywords:
hairy cell leukemia, purine analogs, rituximab, combination therapy, outcome
Organisations:
Cancer Sciences
Identifiers
Local EPrints ID: 358150
URI: http://eprints.soton.ac.uk/id/eprint/358150
ISSN: 1042-8194
PURE UUID: 9fc5d182-d3d7-4c0d-80b0-c45302050305
Catalogue record
Date deposited: 08 Oct 2013 12:51
Last modified: 15 Mar 2024 03:41
Export record
Altmetrics
Contributors
Author:
Francesco Lauria
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
